Companies facing multibillion-dollar exposure from mass-tort personal-injury litigation have faced massive jury verdicts in 2024. In this Votes and Verdicts episode, BI litigation analyst Holly Froum is joined by mass-tort expert and attorney Joseph Fantini to discuss some of the major litigation facing consumer and industrial companies, including cancer claims against Bayer’s Monsanto weedkiller, Zantac lawsuits against drugmakers GSK and others, NEC litigation against Abbott and Reckitt’s Mead Johnson unit and PFAS cases against 3M and other manufacturers. They discuss potential catalysts, the strength of cases, as well as likelihood of potential global settlements.

See omnystudio.com/listener for privacy information.

What are the major impacts to the markets under an administration of former President Donald Trump or Vice President Kamala Harris? What are the risks and opportunities? SkyBridge Capital Co-Founder and Managing Partner Anthony Scaramucci joined Bloomberg Intelligence analysts Nathan Dean and Elliott Stein to discuss the market, sector and other impacts of the US elections. He also discussed his views on the current status of the SEC and whether US policymakers will develop a new regulatory framework for the cryptocurrency industry.

See omnystudio.com/listener for privacy information.

A key TikTok hearing in its fight against the US government’s “sale or ban” law, Coinbase in court to force the SEC to make crypto rules, and Google fighting DOJ antitrust actions on multiple fronts are catalysts to watch in September. In this episode of the Votes and Verdicts podcast, host and Bloomberg Intelligence senior litigation analyst Elliott Stein gathered colleagues to discuss these and other litigation and policy themes. These include trials in the FTC’s challenges to the Kroger-Albertsons and Tapestry-Capri deals, a securities fraud suit against Bausch Health, a trial against Abbott and Reckitt’s Mead Johnson unit over infant formula products, and Robinhood trying to beat class-certification in a customer lawsuit over best execution disclosures. Also discussed were drug-pricing cuts under the Inflation Reduction Act, the impact of Kamala Harris’ policies on the consumer sector and the possibility of the DEA rescheduling marijuana.

See omnystudio.com/listener for privacy information.

In this edition of Bloomberg Intelligence’s Votes & Verdicts podcast, Aude Gerspacher, BI’s senior litigation analyst, and Duane Wright, senior health care policy analyst, discuss the first results of the US government’s Medicare price negotiations, its implications and the outlook for the next list of drugs to be negotiated.

See omnystudio.com/listener for privacy information.

This has been a monumental year for litigation facing historic PFAS manufacturers like 3M, DuPont and Chemours, after the finalization of massive class settlements to cover remediation claims by American water authorities in 1H. Despite those deals, the companies are still up against vast litigation risks. In this episode of Votes and Verdicts, Bloomberg Intelligence litigation analysts Holly Froum and Justin Teresi discuss what’s happened to date and where things are headed — with personal-injury matters, lawsuits by state governments and litigation by settlement opt-outs still on the court’s docket.

See omnystudio.com/listener for privacy information.

Big tech platforms Alphabet, Amazon, Apple and Meta are all ensnared in monopolization lawsuits brought by US antitrust enforcers bent on curbing the power of these companies and seeking, in some cases, court-ordered breakups. Alphabet’s Google recently lost at trial to the Department of Justice in one suit, and heads to court in September in another. What are all of these legal fights about, where do things stand in each suit, and when will they all play out? In this Votes and Verdicts Brief, Bloomberg Intelligence Antitrust Litigation Analysts Jennifer Rie and Justin Teresi discuss these issues.

See omnystudio.com/listener for privacy information.

Co-Executive Director of the AI Now Institute Sarah Myers West and Bloomberg Intelligence analyst Justin Teresi discuss the growth of artificial intelligence and the myriad antitrust policy and litigation considerations underpinning the industry today. In this episode of BI’s Votes and Verdicts podcast, we focus on how antitrust issues are being triggered by AI’s intrinsic need for data, the global race for dominance in the field and investments in smaller startups by larger, established technology companies. We also dig into recent actions by worldwide enforcement agencies and proposed legislation that aims to quell varied antitrust concerns.

See omnystudio.com/listener for privacy information.

New FCC rules on broadband companies being put on hold, a hearing on the FTC’s bid to block the Kroger-Albertsons deal, a potential key ruling in Zantac litigation against GSK and others are catalysts to watch for in August. In this Bloomberg Intelligence litigation and policy outlook episode of the Votes and Verdicts podcast host, BI senior litigation analyst Elliot Stein, gathered colleagues to discuss these and other matters. These include Part D drug-pricing announcements, a Bristol Myers bid to dismiss a suit related to its acquisition of Celgene, a hearing regarding the location of a lawsuit challenging the CFPB’s credit-card late-fee cap and an anticipated ruling to block the FTC’s outlawing noncompete agreements. We also discussed the election’s impact on crypto and healthcare.

See omnystudio.com/listener for privacy information.